Sentiment for Aerie Pharmaceuticals Inc (NASDAQ:AERI)
Aerie Pharmaceuticals Inc (NASDAQ:AERI) institutional sentiment increased to 1.88 in 2019 Q2. Its up 0.46, from 1.42 in 2019Q1. The ratio has increased, as 96 investment professionals started new or increased positions, while 51 cut down and sold their holdings in Aerie Pharmaceuticals Inc. The investment professionals in our partner’s database now hold: 43.63 million shares, up from 43.62 million shares in 2019Q1. Also, the number of investment professionals holding Aerie Pharmaceuticals Inc in their top 10 positions decreased from 6 to 3 for a decrease of 3. Sold All: 19 Reduced: 32 Increased: 66 New Position: 30.
Aerie Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other eye diseases. The company has market cap of $939.63 million. The Company’s lead product candidate includes Rhopressa, a once-daily eye drop for the reduction of intraocular pressure in patients with glaucoma or ocular hypertension. It currently has negative earnings. The firm is also developing Roclatan, a once-daily eye drop to reduce IOP that is in Phase III registration trials to treat patients with open-angle glaucoma and ocular hypertension.
The stock increased 6.32% or $1.2 during the last trading session, reaching $20.28. About 1.37 million shares traded. Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) has declined 67.51% since December 4, 2018 and is downtrending. It has underperformed by 67.51% the S&P500.
Analysts await Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) to report earnings on February, 24. They expect $-0.73 EPS, up 20.65 % or $0.19 from last year’s $-0.92 per share. After $-0.86 actual EPS reported by Aerie Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -15.12 % EPS growth.
Foresite Capital Management Ii Llc holds 27.79% of its portfolio in Aerie Pharmaceuticals, Inc. for 1.67 million shares. Sectoral Asset Management Inc owns 956,036 shares or 3.38% of their US portfolio. Moreover, Consonance Capital Management Lp has 3.15% invested in the company for 1.51 million shares. The California-based Dafna Capital Management Llc has invested 2.28% in the stock. First Light Asset Management Llc, a Minnesota-based fund reported 478,174 shares.
Since January 1, 0001, it had 5 insider purchases, and 0 sales for $5.40 million activity.
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Ratings Coverage
Ratings analysis reveals 100% of Aerie Pharma’s analysts are positive. Out of 7 Wall Street analysts rating Aerie Pharma, 7 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. The lowest target is $3000 while the high is $77. The stock’s average target of $49.57 is 144.43% above today’s ($20.28) share price. AERI was included in 17 notes of analysts from June 21, 2019. The firm earned “Buy” rating on Friday, October 18 by Mizuho. The rating was maintained by Piper Jaffray on Thursday, November 7 with “Overweight”. As per Thursday, October 24, the company rating was maintained by H.C. Wainwright. The stock has “Buy” rating by Mizuho on Friday, October 25. The stock has “Buy” rating by Needham on Friday, October 25. Stifel Nicolaus maintained Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) rating on Thursday, November 7. Stifel Nicolaus has “Buy” rating and $4500 target. On Friday, June 21 the stock rating was maintained by Mizuho with “Buy”. The stock of Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) earned “Overweight” rating by Cantor Fitzgerald on Thursday, August 8. The firm has “Overweight” rating given on Thursday, November 7 by Cantor Fitzgerald. The rating was maintained by Needham with “Buy” on Friday, October 18.
More notable recent Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) news were published by: Finance.Yahoo.com which released: “Does Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Have A Particularly Volatile Share Price? – Yahoo Finance” on June 06, 2019, also Finance.Yahoo.com with their article: “Imagine Owning Aerie Pharmaceuticals (NASDAQ:AERI) While The Price Tanked 62% – Yahoo Finance” published on October 25, 2019, Seekingalpha.com published: “Aerie Pharma receives approval for Rhokiinsa in Europe – Seeking Alpha” on November 21, 2019. More interesting news about Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) were released by: Bizjournals.com and their article: “Aerie buys Spanish outfit as it moves toward profitability – Triangle Business Journal” published on November 19, 2019 as well as Seekingalpha.com‘s news article titled: “Wall Street Brunch – Seeking Alpha” with publication date: December 01, 2019.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.